Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez
{"title":"简要报告：抗癌治疗对胸腺癌患者 COVID-19 治疗结果的影响：CCC19 登记分析","authors":"Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez","doi":"10.1016/j.cllc.2024.04.003","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>Patients with thoracic cancers and COVID-19 have high mortality and morbidity.</p></span></li><li><span>•</span><span><p>Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.</p></span></li><li><span>•</span><span><p>We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).</p></span></li><li><span>•</span><span><p>As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.</p></span></li><li><span>•</span><span><p>None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.</p></span></li><li><span>•</span><span><p>Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.</p></span></li></ul></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis\",\"authors\":\"Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez\",\"doi\":\"10.1016/j.cllc.2024.04.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>•</span><span><p>Patients with thoracic cancers and COVID-19 have high mortality and morbidity.</p></span></li><li><span>•</span><span><p>Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.</p></span></li><li><span>•</span><span><p>We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).</p></span></li><li><span>•</span><span><p>As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.</p></span></li><li><span>•</span><span><p>None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.</p></span></li><li><span>•</span><span><p>Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.</p></span></li></ul></div>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730424000445\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000445","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
•
Patients with thoracic cancers and COVID-19 have high mortality and morbidity.
•
Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.
•
We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).
•
As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.
•
None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.
•
Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
